All Clinical Trials

Clinical Trial NCT04530110

A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age A Study of the Long-Term Safety, Tolerability, and Efficacy of Fremanezumab for Preventing Migraine in Pediatric Patients A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Long-Term Safety Study (Phase 3)

  • ClinicalTrials.gov ID: NCT04530110
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: DERYK LEE WALSH

objective

The primary objective of the study is to evaluate the long-term of fremanezumab for the preventive treatment of episodic or chronic migraine

If you are interested in this clinical trial, please contact Christina Howard on the Children’s Health Research Team.Call 214-456-8559Email